Federal update: DOJ partially rescheduled medical cannabis to Schedule III (April 28, 2026 final order). State-licensed medical operators may apply for expedited DEA registration through June 27, 2026; DEA hearing on full rescheduling set for June 29, 2026.

Residual solvent testing

Residual solvent testing detects and quantifies volatile organic compounds remaining in cannabis extracts, concentrates, and manufactured products after solvent-based extraction (butane or propane hash oil, CO₂, ethanol) and post-processing purges. California's DCC regulates 20 solvents split into two categories aligned with ICH Q3C pharmaceutical classes. Category I compounds (limited to ~1 ppm) include benzene, chloroform, ethylene oxide, methylene chloride, trichloroethylene, and 1,2-dichloroethane — known or suspected carcinogens. Category II compounds have higher ppm action limits: butane and propane (1,000 ppm), pentane, heptane, ethanol, isopropanol, ethyl acetate, acetone (1,000 ppm); hexane (60 ppm); acetonitrile (80 ppm); toluene (180 ppm); xylenes (430 ppm); methanol (600 ppm). The analytical standard is Headspace Gas Chromatography (HS-GC) coupled to Flame Ionization Detection or Mass Spectrometry, with samples sealed in headspace vials heated at 80–140°C. Why it matters: benzene is a confirmed human carcinogen causing leukemia; hexane causes peripheral neuropathy; poor-grade "camping fuel" butane contains benzene and pentane contaminants. Because extracts are vaporized or dabbed at high temperatures, solvents reach the bloodstream directly. → See also: Testing lab, Extraction technician, Manufacturer